Sharemaestro Newsreel

Novartis AG (NVS) Stock Forecasts

Argus Research has raised its target price for Novartis AG (NVS) to $170. The pharmaceutical company, based in Switzerland, focuses on immunology, neuroscience, oncology, and cardiovascular, renal, and metabolic therapies. Argus analyst Jasper Hellweg covers Growth Pharmaceutical, Medical Technology, and Financial Technology companies for …

Novo Nordisk Boosts Treasury Stock as 2026 Share Buyback Passes DKK 7.1 Billion

Novo Nordisk has notably increased its treasury stock as its B-share buyback program for 2026 has exceeded DKK 7.1 billion, representing 1.0% of its share capital. The company launched this repurchase program as part of a larger plan to buy back up to DKK …

Amgen Stock Erased a 17% Drawdown. A MariTide Switch Study Explains Why.

Amgen (AMGN) has raised its 2026 revenue and non-GAAP EPS guidance, driven by strong growth in six key franchises. The company's stock has recovered significantly from a 17% drawdown, largely due to optimism surrounding its new Phase III MariTide SWITCH study, which tests converting …

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen Inc. (AMGN) has attracted investor attention due to its recent stock performance and upcoming earnings report. While the company's shares have shown a 4.9% return in the last month, the Zacks Rank currently rates it as a #4 (Sell), suggesting potential underperformance in …

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN)

AstraZeneca reported solid Q2 2026 core EPS growth, but faces significant risks due to the patent expiry of its key treatment, Farxiga, in the U.S. and its inclusion in China's procurement program. While the company's weight loss drug candidate offers some positive offsets, the …

Grifols, S.A. $GRFS Shares Sold by Whitebox Advisors LLC

Whitebox Advisors LLC reduced its stake in Grifols, S.A. by 21.1% in Q1 2026, selling 553,670 shares but still retaining over 2 million shares. Despite this, other major institutional investors like Royal Bank of Canada and Goldman Sachs increased their positions in the biotechnology …

Flat Footed LLC Buys 287,867 Shares of Grifols, S.A. $GRFS

Flat Footed LLC significantly increased its stake in Grifols, S.A. (NASDAQ:GRFS) during the first quarter, purchasing an additional 287,867 shares to bring its total holding to 1.37 million shares valued at approximately $11.0 million. Other institutional investors like Brandes Investment Partners, Norges Bank, and …

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S has initiated a share repurchase program as part of a larger plan to buy back up to DKK 15 billion in shares over a 12-month period. Since May 6, 2026, the company has been repurchasing B shares, with accumulated transactions totaling …

Grifols SA (GRFS) Institutional Confidence

Grifols SA (GRFS) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. Institutional shareholding increased by 2.67% quarter-over-quarter to 57.68%, with Brandes Investment Partners being the largest shareholder despite decreasing their holdings.

Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB

Orbimed Advisors LLC has acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the first quarter, investing approximately $11.29 million for 61,600 shares. This investment comes as several other hedge funds also adjusted their positions in the biotechnology company. Biogen recently reported strong quarterly …

Orbimed Advisors LLC Purchases Shares of 39,900 Amgen Inc. $AMGN

Orbimed Advisors LLC has acquired 39,900 shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, totaling approximately $14,039,000. Several other institutional investors also increased their holdings in Amgen, which currently has 76.50% institutional ownership. Amgen recently reported strong quarterly earnings, beating analyst estimates, and …

Bristol-Myers Squibb stock hits 52-week high at 62.89 USD

Bristol-Myers Squibb (BMY) stock recently hit a new 52-week high of $62.89, trading at $62.95 with a market capitalization of $127.94 billion. The company has maintained dividend payments for 56 consecutive years, currently yielding 4.06%. This milestone follows the FDA's acceptance of their New …

Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy (NYSE:NVO)

Novo Nordisk (NVO) has received a "Modest Buy" rating with a raised price target of $80, primarily driven by the rapid market adoption of its oral Wegovy. The drug has achieved over 3 million prescriptions in five months, largely from new GLP-1 patients, indicating …

Family Manage LLC Raises Holdings in Merck & Co., Inc. $MRK

Family Manage LLC significantly increased its stake in Merck & Co., Inc. by 778.2% in the first quarter, now owning 35,495 shares valued at $4.27 million. Institutional investors collectively hold 76.07% of Merck's stock, which recently reported strong first-quarter revenue and an attractive dividend …

Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer?

Pfizer (PFE) is currently undervalued, trading at US$24.54 against a fair value of $29.19, following the FDA's Priority Review acceptance for TALZENNA plus XTANDI in prostate cancer. This oncology update comes after a mixed period for the stock, though shorter-term momentum has improved. Investors …

AstraZeneca shares climbs as full-year outlook reiterated despite recent trial failure - UPDATE

AstraZeneca's shares rose after the drugmaker reported better-than-expected second-quarter earnings, driven by strong growth in oncology and rare diseases. Despite a recent trial failure that impacted its valuation, the company reiterated its full-year revenue and core earnings per share growth outlook. CEO Pascal Soriot …

Johnson & Johnson Now Leads Its Pitch With An Oncology Bet

Johnson & Johnson (JNJ) has shifted its core strategy from broad diversification to a concentrated bet on oncology, aiming to be the number one oncology company by 2030 with over $50 billion in sales. While the company's overall revenue growth remains strong, its net …

AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation (NYSE:AZN) 2026-07-27

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth (AZN:NYSE)

Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings (NYSE:NVO)

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Moderate Buy" by Analysts

Biogen Inc. (NASDAQ:BIIB) has received a consensus "Moderate Buy" rating from 32 analysts, with an average 12-month price target of $220.57. This target is higher than its current share price of $202.19, reflecting positive sentiment from several firms. The company also reported strong quarterly …

Astrazeneca: Q2 Earnings Snapshot

This article provides a brief earnings snapshot for Astrazeneca's Q2 results. However, the actual financial details and performance metrics are not included in the provided text.

AstraZeneca's Q2 revenue rises 6% to $15.4B

AstraZeneca reported a 6% increase in its second-quarter revenue, reaching $15.4 billion. This financial update indicates continued growth for the pharmaceutical company.

Gilead (GILD) Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

Gilead Sciences received a positive opinion from the European Medicines Agency’s CHMP for Trodelvy combined with Keytruda to treat PD-L1 positive metastatic triple-negative breast cancer. This recommendation is based on strong Phase 3 data showing reduced disease progression or death. The European Commission's subsequent …

Earnings Flash (AZN.L) AstraZeneca PLC Reports H1 Revenue $30.67B

AstraZeneca PLC (AZN.L) reported its H1 revenue to be $30.67 billion. This financial update comes alongside recent news regarding the company's drug trials, including Ultomiris missing its primary endpoint in a late-stage trial. Despite some setbacks, AstraZeneca posted a rise in H1 profit and …

Biogen stock trades steady as Alzheimer’s franchise and pipeline shape earnings outlook

Biogen (BIIB) stock is navigating a transition as it balances slowing revenue from older multiple sclerosis products with the growth potential of its Alzheimer's drug Leqembi and a refocused neurology pipeline. The company reported $9.83 billion in revenue and $1.7 billion in net income …

Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop

Novartis reported Q2 net sales up 1-3% and beat EPS estimates, but experienced a 50% drop in Entresto sales due to U.S. generics. Despite this, the company reiterated its full-year guidance and is investing heavily in acquisitions and manufacturing expansion, with key trial readouts …

Merck stock holds firm as oncology revenue supports valuation

Merck & Co. (ISIN US58933Y1055) continues to be supported by its strong oncology franchise, particularly the cancer drug Keytruda, which drives significant revenue growth. This performance helps offset the impact of patent expiries and fluctuating vaccine demand. Investors are closely monitoring Keytruda's sustained double-digit …

OGN|Organon & Co|Price:13.560|

Grifols SA (GRFS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Mira Pharmaceuticals Inc (MIRA) Income Statement

This article provides the quarterly and annual income statements for Mira Pharmaceuticals Inc (MIRA), offering detailed financial data on total revenue, operating expenses, R&D expenses, operating profit, and net income. It includes historical data from FY2021Q1 to FY2026Q1, highlighting key financial metrics and year-over-year …

Novo Nordisk: Initiating Buy, Calling The Bottom (NYSE:NVO)

Willow Tree Research initiates coverage on Novo Nordisk (NVO) with a "BUY" rating and a $68 price target, believing its current valuation presents an attractive entry point. The expansion of the treated obesity market by oral Wegovy, along with a robust pipeline, is expected …

Eli Lilly and Company (LLY) Stock Price, News, Quote & History

This page provides comprehensive information on Eli Lilly and Company (LLY), including its current stock price of $1,159.34, up 1.08%, and detailed financial data. It highlights the company's product portfolio in cardiometabolic health, oncology, and immunology, and recent news, notably a lawsuit from Novo …

Gilead Sciences (GILD) Gets a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD) with a price target of $120.00. Goldman Sachs also issued a Hold rating, while BMO Capital assigned a Buy rating. Gilead reported Q1 revenue of $6.96 billion and a net profit …